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Abstract
Background: Improving the treatment of renal cell carcinoma (RCC) will depend on the development of better
biomarkers for predicting disease progression and aiding the design of appropriate therapies. One such marker
may be fatty acid binding protein 7 (FABP7), also known as B-FABP and BLBP, which is expressed normally in radial
glial cells of the developing central nervous system and cells of the mammary gland. Melanomas, glioblastomas,
and several types of carcinomas, including RCC, overexpress FABP7. The abundant expression of FABP7 in primary
RCCs compared to certain RCC-derived cell lines may allow the definition of the molecular components of FABP7’s
regulatory system.
Results: We determined FABP7 mRNA levels in six RCC cell lines. Two were highly expressed, whereas the other
and the embryonic kidney cell line (HEK293) were weakly expressed FABP7 transcripts. Western blot analysis of the
cell lines detected strong FABP7 expression only in one RCC cell line. Promoter activity in the RCC cell lines was 3-
to 21-fold higher than that of HEK293. Deletion analysis demonstrated that three FABP7 promoter regions
contributed to upregulated expression in RCC cell lines, but not in the HEK293 cell. Competition analysis of gel
shifts indicated that OCT1, OCT6, and nuclear factor I (NFI) bound to the FABP7 promoter region. Supershift
experiments indicated that BRN2 (POU3F2) and NFI bound to the FABP7 promoter region as well. There was an
inverse correlation between FABP7 promoter activity and BRN2 mRNA expression. The FABP7-positive cell line’s NFI-
DNA complex migrated faster than in other cell lines. Levels of NFIA mRNA were higher in the HEK293 cell line
than in any of the six RCC cell lines. In contrast, NFIC mRNA expression was lower in the HEK293 cell line than in
the six RCC cell lines.
Conclusions: Three putative FABP7 promoter regions drive reporter gene expression in RCC cell lines, but not in
the HEK293 cell line. BRN2 and NFI may be key factors regulating the expression of FABP7 in certain RCC-derived
cell lines.
Background
Among primary renal tumors the most common is renal
cell carcinoma (RCC). Although earlier detection of
RCC has positively influenced patient outcomes [1], pre-
dicting both disease progression and patient response to
treatment is difficult, due in part to the lack of suitable
molecular markers [2].
FABP7 belongs to a mammalian family of at least nine
proteins that are specifically expressed in diverse tissues
such as liver, intestine, heart, adipose tissue, epidermis,
brain, peripheral nervous system, and testis [3]. Several
members of the FABP family play important roles in
regulating metabolism and have been implicated in con-
tributing to the development of insulin resistance and
the metabolic syndrome [4].
Studies on human tumors and tumor-derived cell lines
have indicated both FABP7’s potential involvement in
tumorigenesis and usefulness as a tumor marker [5-16].
Expression analyses have demonstrated FABP7
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[5-8], as well as in tissues in those with glioblastoma [9]
and melanoma [10,11]. FABP7 mRNA [5-8] and FABP7
protein [5,6,8] are overexpressed in RCC. FABP7 over-
expression correlates with shorter survival in patients
with glioblastoma [9,12,13] and melanoma [10,14,11],
but better outcomes in those with breast cancer [15].
FABP7’sr o l ea sat u m o rs u p p r e s s o ri ss u g g e s t e db yt h e
finding that its enforced overexpression inhibits prolif-
eration of a breast cancer cell line [16]. These findings
clearly indicate the importance of determining how
FABP7 expression is regulated. NFI and Pbx/POU bind-
ing sites have been found to be present in the FABP7
promoter in humans [17-19]. In glioma cell lines, NFI
dephosphorylation is correlated with FABP7 expression
[17]. In fact, all four members of the NFI family of tran-
scription factors play key roles in the regulation of
FABP7 in glioma cell lines [18]. Sánchez-Font et al. have
suggested that FABP7 overexpression, controlled by the
transcription factor PKNOX1, contributes to Down Syn-
drome-associated neurological disorders [19].
Here, we investigated the molecular mechanisms con-
trolling FABP7 expression in human RCC cell lines.
Results
FABP7 expression by RCC cell lines
We previously analyzed FABP7 mRNA expression in
primary surgically resected RCCs and were able to
detect FABP7 mRNA in the tumor, but not in normal
tissue [6,7]. Figure 1A and Additional file 1 show the
results of real-time polymerase chain reaction (quantita-
tive PCR; Q-PCR) analysis of six RCC cell lines for
FABP7 transcripts. Two RCC cell lines (OS-RC-2 and
TUHR14TKB) exhibited strong FABP7 expression, in
contrast to four other RCC cell lines (769-P, 786-O,
ACHN and Caki-1) and a human embryonic kidney cell
line (HEK293). These results differ from our analysis of
primary RCCs, which expressed FABP7 at high fre-
quency (80%) [7]. We also performed Western blot ana-
lysis for FABP7 expression in these same cell lines
(Figure 1C, Additional file 2). A band corresponding to
the major 15 kDa isoform [12] was detected at the high-
est level in TUHR14TKB, whereas it was not detectably
expressed by HEK293 and other RCC cell lines (Figure
1C). The19 kDa FABP7 isoform potentially generated by
alternative splicing (AK289836, AL512688; [20]) was not
detected (Additional file 2).
Cis-acting elements in the FABP7 promoter
We prepared FABP7-luciferase constructs to determine
the location of 5’-flanking FABP7 regulatory elements
active in RCC cell lines. All promoter constructs extend
from 89 base pairs (bp) downstream from the transcrip-
tion start site to various upstream sites as described in
Figure 2. The promoter activity of the -1122 to +89
FABP7 fragment in RCC cell lines was 3- to 21-fold
higher than that of HEK293 (Figure 1B andAdditional
file 1). FABP7 promoter activity did not correlate with
mRNA and protein expression. The promoter deletion
analyses shown in Figure 3A and Additional file 1
demonstrates the presence of a strongly positive cis-reg-
ulatory element between nucleotide positions -192 and
-36. Interestingly, a relatively small increase (3 fold) was
exhibited by the HEK293 transfectant (Figure 3A, Addi-
tional file 1). In order to more precisely localize the pro-
moter site, we conducted detailed deletion analysis
between positions -192 and -36, summarized in Figure
3B and Additional file 1. Interestingly, the positive regu-
latory region between -83 and -36 was more active in
RCC cell lines than in HEK293, so we conducted more
detail deletion analysis of the region between positions
-83 and -36 (Figure 3C, Additional file 1). Compared to
the promoter activity of -36+89 construct transfectant, a
2 to 3 fold increase in luciferase activity was observed
with the -72+89 transfectant. In contrast, no increase
was observed in HEK293 (Figure 3C, Additional file 1).
The results demonstrate the presence of multiple posi-
tive cis-regulatory elements within the region bounded
by nucleotides -72 to -36.
Transcription factor binding to the FABP7 promoter
We analyzed the FABP7 promoter region in silico using
the TFBIND [21] and TESS [22] programs and by visual
inspection with the TESS [22] to identify transcription
factors binding to the FABP7 promoter of -72 to -36.
OCT1, OCT6, BRN2, C/EBP-a, NFI, C/EBP-b, YY1, and
SP1 binding sites were found across the promoter
region (-73 to -28 bp) (Figure 4).
We next performed mobility shift assays to determine
the factors binding to the three RCC-specific up-regu-
lated regions of the FABP7 promoter. Three double-
stranded oligonucleotides named upstream probe (UP),
middle probe (MP), and downstream probe (DP) (Table
1 and Figure 4), which represent the active regions
within the -73 to -28 sequence (-72 to -61 bp, -61 to
-48 bp, and -48 to -36 bp) and used the double stranded
oligonucleotides as gel shift probes.
The UP detected a major band migrating at the same
position in all nuclear extracts, and an additional
HEK293-specific species (Figure 5A). A common shifted
band (black arrows) was observed that could be com-
peted by the addition of excess amounts of cold double-
stranded OCT1 or OCT6 oligonucleotides (Figure 5B).
However, the addition of anti-OCT1 or anti-OCT6 anti-
body to the binding reaction did not change the band
shift pattern (Figure 5C). Interestingly, the addition of
excess amounts of C/EBP-a,O C T 1 ,o rO C T 6p r o b e s
shifted the bands up (yellow arrows) (Figure 5B). We
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vent weak protein-DNA binding shifted up by addition
of the cold probe.
To investigate whether the HEK293-specific band (yel-
low arrow, Figure 5A) was BRN2-dependent, addition of
BRN2 antibody to the reactions resulted in a supershift
(indicated by the * in Figure 5C). We could not make
clear the reason why BRN2 oligonucleotide did not
change the band shift pattern. It might be the effect of
band shift that shifted up the addition of excess
amounts of probe (yellow arrows, Figure 5B). To
demonstrate the specificity of the BRN2 antibody used
Figure 1 FABP7 expression in RCC cell lines. A) Q-PCR analysis was performed using total RNA extracted from a human embryonic kidney
(HEK293) and RCC (TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cell lines. FABP7 expression was determined with Q-PCR by the
primers listed in Table 2. B) HEK293 and RCC (TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cells were cotransfected with the -1122+89
pGL4-FABP7 promoter construct, and cultured for one day. Extracts prepared from transfected cells were assayed for luciferase activity. FABP7
promoter activities were normalized to the control’s Renilla luciferase activity. The results shown are an average of four independent experiments
with standard deviations indicated by the error bars. C) Western blot analysis was performed using cytoplasmic extracts from HEK293 and RCC
(TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cell lines.
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Page 3 of 12Figure 2 The pGL4-FABP7 promoter constructs. Schematic diagram of the FABP7 promoter showing the transcription start site (arrow, [17])
and coding regions (filled box). The pGL4-FABP7 promoter constructs extended from a common site +89 bp from the transcription start site to
sites upstream (-36, -48, -61, -72, -83, -149, -192, -351, -468 and -1122 bp) were prepared by ligating PCR products to pGL4.17.
Figure 3 FABP7 promoter deletion analysis. HEK293 and RCC (TUHR14TKB, 786-O, 769-P, OS-RC-2, Caki-1, and ACHN) cells were cotransfected
with the pGL4-FABP7 promoter constructs described above and the pGL4.74 plasmid control, and cultured for one day. Extracts prepared from
transfected cells were assayed for luciferase activity. FABP7 promoter activities were normalized to the control’s Renilla luciferase activity. The
results shown are an average of at least three independent experiments with standard deviations indicated by the error bars. A: Deletion analysis
of the FABP7 promoter region. B, and C: analyses of additional deletions.
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band detected by Western blot analysis was weaker
when BRN2 was depleted using small interfering RNA
(siRNA) (Figure 6B). Furthermore, the HEK293-specific
shifted band (yellow arrow, Figure 6C) was not apparent
in BRN2 specific siRNA transfectant.
RCC cell lines expressed more than five times less
BRN2 mRNA than HEK293s (Figure 7A andAdditional
file 1) and BRN2 protein expression was higher in
HEK293 than RCC cell lines (Figure 7B). There was an
inverse correlation between FABP7 promoter activity
(Figure 1B) and BRN2 mRNA expression (Figure 7A), in
HEK293s and RCCs (correlation coefficient, r = -0.73,
Additional file 1). This result indicates that BRN2
represses the FABP7 promoter.
Bisgrove et al. reported that NFI binds to the region
bounded by nucleotides -54 to -40 bp of the FABP7
promoter [17], corresponding to the middle probe (MP),
and point mutations in this region attenuate FABP7
promoter activity. When we performed gel shift analysis
with MP, a major DNA-protein complex was observed
in all seven cell lines (Figure 8A). The band marked by
the blue arrow was competed by an NFI oligonucleotide
in HEK293 cell line and TUHR14TKB cell line (Figure
8B). Addition of the anti-NFI antibody to the binding
reaction supershifted the NFI-DNA complex in HEK293
and TUHR14TKB cell lines (indicated by the * in Figure
8C). TUHR14TKB’s NFI-DNA complexes migrated dif-
ferently than those of the other cell lines (Figure 8A).
FABP7 expression (Figure 1C) correlated with FABP7
promoter activation (-61 to -48 bp) (Figure 3C and
Additional file 1) and NFI gel shift patterns (Figure 8A).
The NFI transcription factor family includes four
genes: NFIA, NFIB, NFIC and NFIX [23]. In an effort to
Figure 4 FABP7 promoter cis-regulatory region identified by promoter deletion analysis. Numbering starts from the FABP7 transcription
start site [17]. Oligonucleotides designated upstream (UP), middle (MP) and downstream (DP) probes are shown along with putative consensus
binding sites for OCT1, C/EBP-a, BRN2, OCT6, NFI, C/EBP-b, SP1, and YY1.
Table 1 Gel shift probes
Name Sequence Sense or Antisense
Upstream probe TGTGTTTGCAATTTAAATCACTGGA
TCCAGTGATTTAAATTGCAAACACA
Middle probe TAAATCACTGGATTTTTGCCCAC
GTGGGCAAAAATCCAGTGATTTA
Downstream probe TTTTTGCCCACCCTCTTTCCAAA
TTTGGAAAGAGGGTGGGCAAAAA
C/EBP alpha TCTTTGGAAAGGT
ACCTTTCCAAAGA
OCT1 GTAAATGCAAATCAG
CTGATTTGCATTTAC
BRN2 GCCATTCGAAATGAGC
GCTCATTTCGAATGGC
OCT6 GAGGAATTAGACTGC
GCAGTCTAATTCCTC
NFI TCTTGGCAAGAAGCCAAG
CTTGGCTTCTTGCCAAGA
C/EBP beta AGCTTGCACAACTC
GAGTTGTGCAAGCT
YY1 GATAACCATTTTTGAAC
GTTCAAAAATGGTTATC
SP1 TGAGGCAGGGT
ACCCTGCCTCA
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interact with the FABP7 promoter, we determined NFI
family members’ mRNA levels. NFIA and NFIC mRNA
levels were, respectively, weaker and stronger in all six
RCC cell lines than in HEK293 (Figure 7C). NFIB and
NFIX mRNA levels were approximately the same in all
seven cell lines (Figure 7C).
When DP was subjected to gel shift analysis, only one
weak band was observed (Additional file 3A). This band
did not compete with any of the oligonucleotides repre-
senting transcription factor binding sites, whereas addi-
tion of excess amounts of C/EBP-b probe shifted the
band up (Additional file 3B). In contrast, addition of
YY1 antibody did not alter this band’s mobility (Addi-
tional file 3C).
Discussion
Approximately 70% of RCC patients survive for 5 years.
However, the presence of distant metastases dramati-
cally lowers survival, indicating the importance of devel-
oping better biomarkers for predicting disease course
and designing suitable therapies. Overexpression of
FABP7 in tumor tissue and urine of patients with RCC,
[5-8] led us to consider FABP7 as such a biomarker and
to elucidate the regulation of its expression.
As an initial approach, we chose to study FABP7
expression in cell lines derived from human RCCs and
embryonic kidney. Our finding of strong FABP7 mRNA
expression by two of six RCC cell lines (Figure 1A) var-
ies from our previous finding of 80% (n = 54) overex-
pression by carcinoma compared to corresponding
expression in normal tissues [7]. Seliger et al. conducted
studies related to ours that demonstrated FABP7 tran-
scripts in 18 of 27 clear cell-type RCC lesions but only
4 of 19 RCC cell lines [5]. These observations may
reflect the fact that higher grade (G3 + G4) versus lower
grade (G1 + G2) tumors expressed significantly lower
FABP7 mRNA levels [8]. Furthermore, ACHN and
Caki-1 cell line, which expressed FABP7 mRNA weaker
than other (Figure 1A), isolated from malignant pleural
effusion and cutaneous metastasis each [24,25]. And
FABP7 mRNA expression of 786-O cell lines was
weaker than that of 769-P cell lines (Figure 1A). That
RCC cases with poorer prognoses tend to express lower
FABP7 levels, is consistent with the fact that the 786-O
cell line was isolated from a patient with a prognosis
less favorable than the patient from which the 769-P
cell line was derived [26]. Several parallel studies have
been conducted using other tumors. For example, pri-
mary versus metastatic melanomas express higher
FABP7 mRNA levels [11]. FABP7-positive, compared to
FABP7-negative, breast cancer patients experienced sig-
nificantly longer disease-free survival and breast cancer
specific survival [15]. The role of FABP7 as a tumor
suppressor in human mammary cells is suggested by the
demonstration that its enforced overexpression inhibits
breast cancer cell proliferation [16]. In contrast, a recent
study showed that down-regulating FABP7 using RNA
interference techniques inhibited cell proliferation and
migration but did not affect the invasive properties of
the Caki-2 RCC cell line [27]. This suggests that the
role of FABP7 in tumorigenesis depends on cell-specific
regulatory factors.
We noted a discrepancy between endogenous FABP7
mRNA expression and the activity of the FABP7 promo-
ter in cell lines derived from RCCs (786-O, ACHN,
Figure 5 Gel shift analysis with the UP probe.A )
32P-labeled UP
(Table 1 and Figure 4) were added to HEK293 or RCC (Caki-1, OS-
RC-2, TUHR14TKB, 769-P, 786-O, and ACHN) nuclear extracts. In (+)
cell line, luciferase activity of -72+89 vector transfectant was
increased above 30% than that of -61+89 vector transfectant.
Arrowheads indicate significant band shifts. B) Competition analysis.
Table 1 describes the oligonucleotide sequences. A 100-fold excess
of unlabeled oligonucleotide indicated in the figure was added to
each reaction. C) Five micrograms of HEK293 or ACHN nuclear
extracts were incubated with 2 μg of antibody (see figure) on ice
for 30 min prior to addition of the
32P-labeled oligonucleotide
probes. The ‘*’ shows anti-BRN2 induced supershifts.
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Page 6 of 12Figure 6 BRN2 knockdown. HEK293 cells were transfected with scrambled (SC) or BRN2 (BRN2.1 or BRN2.2) siRNAs. A) Q-PCR analysis for BRN2
to confirm efficient BRN2 knockdown. BRN2 was amplified using the primers shown in Table 2. B) Western blot analysis of BRN2 expression to
confirm efficient BRN2 knockdown. C) Gel shift analysis for BRN2 specific band shift.
32P-labeled UP (Table 1 and Fig. 4) was added to nuclear
extracts (5 μg) prepared from HEK293 cells transfected with scrambled (SC) or BRN2 (BRN2.1 or BRN2.2) siRNAs. Arrowheads indicate significant
band shifts.
Figure 7 Expression of transcription factor binding to FABP7 promoter. A) Q-PCR analysis was performed using total RNA extracted from a
human embryonic kidney (HEK293) and RCC (TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cell lines. BRN2 was amplified using the
primers shown in Table 2. B) Western blot analysis was performed using nuclear extract from a human embryonic kidney (HEK293) and RCC
(TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cell lines. C) RT-PCR analysis was performed using total RNA extracted from a human
embryonic kidney (HEK293) and RCC (TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cell lines. OCT6, OCT1, NFIA, NFIB, NFIC,o rNFIX
cDNAs were amplified using the primers shown in Table 2.
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(HEK293) (Figure 1A and 1B). These results are remi-
niscent of the report demonstrating that neither NFIC
nor NFIX overexpression had any effect on endogenous
FABP7 transcript levels although their overexpression
decreased exogenous FABP7 promoter activity to 50%
[18].
A possible explanation for this discrepancy is the
nucleosomal organization of a chromosomal versus an
episomal promoter. The basic unit of chromatin is the
nucleosomal core particle, containing 147 bp of DNA
that wraps twice around an octamer of core histones.
T h ec o r eh i s t o n e sb e a rah i g h l yd y n a m i cN - t e r m i n a l
amino acid tail approximately 20-35 residues long and
rich in basic amino acids. These tails, which extend
from the surface of the nucleosome, play an important
role in folding of nucleosomal arrays into higher order
chromatin structures that perform important functions
in eukaryotic gene regulation [28]. Methylation of pro-
moter CpG islands can play important roles in gene
silencing [29]. However, this mechanism does not likely
apply to human FABP7, since its promoter lacks a CpG
island. We propose that an as-yet unidentified cis-acting
negative regulatory element(s) residing either farther
upstream or downstream from the region we analyzed
in this study may explain the discrepancy between
FABP7 mRNA levels and promoter activity.
Gene expression can be negatively regulated post-tran-
scriptionally by microRNAs (miRNAs) [30], which play
significant roles in cellular transformation and carcino-
genesis by acting either as oncogenes or tumor suppres-
sors [31]. A mechanism involving miRNAs may explain
the discrepancy between FABP7 mRNA and protein
expression levels.
Bisgrove et al. [17] reported that NFI is a key tran-
scriptional activator of the FABP7 promoter in glioma
cell lines. Our FABP7 promoter analysis reported here
also showed that deletion of the NFI binding site down-
regulated promoter activity in the TUHR14TKB cell line
(Figure 3C), the only cell line positive for FABP7 protein
expression. In glioma cell lines [17], NFI-DNA com-
plexes were converted to a faster-migrating form by
potato acid phosphatase treatment, indicating NFI acti-
vation by dephosphorylation [17]. Our gel shift analysis
also revealed a similar association between the presence
of a faster-migrating band (Figure 8A), FABP7 promoter
Figure 8 Gel shift analysis with the MP probe.A )
32P-labeled MP (Table 1 and Fig. 4) was added to HEK293 or RCC (ACHN, OS-RC-2, 769-P,
786-O, Caki-1, and TUHR14TKB) nuclear extracts. In (+) cell line, luciferase activity of -61+89 vector transfectant was increased above 30% than
that of -48+89 vector transfectant. Arrowheads indicate significant band shifts. B) Competition analysis was performed using a variety of
oligonucleotides (Table 1). A 100-fold excess of unlabeled competitor oligonucleotide, indicated in the figure, was added to each reaction. C)
Five micrograms of HEK293 or TUHR14TKB nuclear extracts were incubated with 2 μg of the antibodies, as indicated in the figure, on ice for 30
min prior to addition of the
32P-labeled oligonucleotide probes. The ‘*’ indicates anti-NFI induced supershifts.
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(Figure 1C).
NFIA and NFIC were, respectively, weaker and stron-
ger in all six RCC cell lines than in HEK293 (Figure
7C). In a glioma cell line, NFIA and NFIC siRNAs
inhibited and enhanced FABP7 promoter activity,
respectively [18], thus indicating that FABP7 promoter
activity in RCC cell lines may be weaker than that in
the HEK293 cell line. This discrepancy might be attribu-
ted to a difference in FABP7 promoter regulation of
NFIA and NFIC in RCC cell lines and glioma cell lines.
Deletion of the mouse Brn2 locus results in loss of
specific neuronal lineages in the hypothalamus and con-
sequent loss of the posterior pituitary gland [32,33]. A
combination of three factors, Ascl1, Brn2 and Myt1l,
suffice to rapidly and efficiently convert mouse embryo-
nic and postnatal fibroblasts into functional neurons in
vitro [34]. BRN2 may coordinate normal melanocytic
differentiation, whereas BRN2 can be re-activated in
melanoma and may play a role in melanoma cell prolif-
eration and tumorigenesis [35]. BRN2 also plays an
important role in keratinocyte differentiation and in the
pathogenesis of lichen planus lesions [36]. Our results
indicate that BRN2 represses the FABP7 promoter and
suggests that regulation of FABP7 expression by BRN2
differs between RCCs and melanomas.
There is a contradiction between gel shift analysis by
competing with OCT1 or OCT6 probe (Figure 5B) and
gel shift analysis adding anti-OCT1 or anti-OCT6 anti-
body (Figure 5C). One probability is that OCT1 and
OCT6 probes bind to other transcription factor. How-
ever, it might be rare case for one transcription factor
to bind to FABP7 promoter, OCT1 and OCT6 probes.
Zwilling et al. reported that OCTl and OCT6 interact
with high mobility group protein 2 [37]. This indicates
that high mobility group protein 2 may form complex
with OCT1 and OCT6. This putative complex may
reflect band shift of upstream element competing with
OCT1 and OCT6. Furthermore, OCT1 and OCT6
formed dimer on the consensus MORE [38]. Same com-
plex may form on upstream element of FABP7 promo-
ter. Forming OCT1-OCT6 complex might be disturbed
in binding anti-OCT1 and anti-OCT6 antibodies to
OCT1 and OCT6 respectively. Other possibility is that
anti-OCT1 and anti-OCT6 antibodies cannot bind to
OCT1 and OCT6 in our gel shift condition.
Our present finding that RCC cell lines differentially
express FABP7 transcripts and protein, in contrast to
the almost uniform overexpression of FABP7 transcripts
by primary tumors, indicate the value of RCC cell lines
for deciphering the mechanisms responsible for control-
ling FABP7 expression. Our future studies will focus on
analyses of additional RCC cell lines to determine
whether the low frequency of FABP7 expression is a
consequence of selecting tumor cells for in vitro growth,
and if so, will provide new insights into regulation of
FABP7 expression. It will be important to determine
whether primary tumors express FABP7 at the same
high level as its transcript. If so, this would provide
compelling evidence for FABP7’s etiological role in
RCC, and encourage future studies to evaluate it as a
diagnostic marker and as a therapeutic target.
Conclusions
A high percentage of primary RCCs, but not RCC-
derived cell lines, express high FABP7 mRNA. The tran-
scription factor BRN2 binds to the cis-acting regions in
the FABP7 promoter identified in the present studies.
BRN2 may repress the FABP7 promoter, because its
expression inversely correlates with FABP7 promoter
activity. NFI may also regulate FABP7 expression.
Future studies will focus on analyzing these and other
regulatory molecules in order to help design new thera-
pies for treating RCC.
Methods
Reagents
Reagents and their sources were the following: GIBCO
®
RPMI Media 1640, oligo (dT)12-18,S u p e r S c r i p t
® III
Reverse Transcriptase and pCR
®2.1-TOPO
® vector,
Invitrogen Corp. (Carlsbad, CA); SYBR
® Green PCR
Master Mix, Life Technologies (Carlsbad, CA); Oligo-
peptides and siRNAs, Hokkaido System Science (Sap-
poro, Hokkaido, Japan); Complete Protease Inhibitor
Cocktail, FuGENE
® HD Transfection Reagent, poly (dI-
dC) and X-tremeGENE siRNA Transfection Reagent,
Roche Diagnostics GmbH (Mannheim, Germany); BCA
Protein Assay Reagent Kit and NE-PER Nuclear and
Cytoplasmic Extraction Reagents, Thermo Fisher Scien-
tific (Waltham, MA); Immobilon Western HRP Sub-
strate, Millipore (Billerica, MA); HEPES, spermidine and
dithiothreitol, Sigma-Aldrich (St. Louis, MO); PVDF
membrane and Illustra MicroSpin G-25 columns, GE
Healthcare UK Ltd. (Little Chalfont, Buckinghamshire
HP7 9NA, England); pGL4.17 and pGL4.74 plasmids
and Dual-Luciferase
® Reporter (DLR™)A s s a yS y s t e m ,
Promega (Madison, WI); restriction endonucleases and
DNA Ligation Kit Ver.2.1, TAKARA BIO INC. (Otsu,
Shiga, Japan); [g-
32P] dATP, Perkin Elmer Inc. (Wal-
tham, MA); T4 Polynucleotide Kinase, Toyobo (Osaka,
Japan); KCl, glycerol and NP-40, Wako (Osaka, Japan).
Cell culture
RCC cell lines (786-O, 769-P and ACHN) were pur-
chased from the American Type Culture Collection
(Manassas, VA). Caki-1,H E K 2 9 3 ,O S - R C - 2 ,a n d
TUHR14TKB were provided by the RIKEN (Tsukuba,
Ibaraki, Japan). All cell lines were grown in GIBCO
®
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Page 9 of 12RPMI Media 1640 supplemented with 10% (v/v) fetal
bovine serum (Nichirei Biosciences Inc., Japan). Cells
were cultured at 37°C in a humidified atmosphere con-
taining 5% (v/v) CO2.
RT-PCR and Q-PCR analysis
Cells were cultured in 100 mm dishes for two days.
Total RNA was isolated from cultured cell lines using
the RNeasy Mini Kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions. Either 5 μg
or 3 μg RNA was reverse transcribed using the Super-
Script
® III Reverse Transcriptase primed by 500 ng of
oligo (dT)12-18 according to the manufacturer’sr e c o m -
mendations. PCR amplification was performed using 1
μL of first-strand complementary DNA (cDNA) as tem-
plate with the primers and number of cycles listed in
Table 2. Amplified DNA was analyzed by electrophor-
esis through 2% or 3% (w/v) agarose gels. Q-PCR analy-
sis of FABP7 and BRN2 expression in RCC and HEK293
cell lines were done with the Applied Biosystems StepO-
nePlus™ (Life Technologies). The final PCR reaction
mix included 2 μLo f5μM specific primer, 1 μLf i r s t -
strand cDNA and 10 μL SYBR
® Green PCR Master Mix
at a final volume of 20 μL. Specific plasmid controls for
FABP7, BRN2 and TBP were synthesized as the direct
insertion of PCR products into a pCR
®2.1-TOPO
® vec-
tor, and standard curves for each marker were generated
with seven serial dilutions of plasmid templates (0.1 nM
to 0.1 fM). TBP w a su s e da sa ni n t e r n a lc o n t r o l .T h e
sense primer for FABP7 amplification, primers for TBP
amplification and primers for OCT6 amplification were
reported by Teratani et al. [7], Jung et al. [39] and Faus
et al. [40], respectively.
Antibodies
An anti-human FABP7 Antibody (AF3166) was purchased
f r o mR & DS y s t e m s ,I n c .P e r o x idase-conjugated donkey
anti-goat IgG (86285) was purchased from Jackson Immu-
noResearch Laboratories, Inc. (West Grove, PA). A mouse
monoclonal anti-a-tubulin antibody (T6074) was pur-
chased from Sigma-Aldrich (St. Louis, MO). Goat anti-
mouse IgG-HRP (sc-2005), anti-Brn-2 (C-20: sc-6029 X),
anti-Lamin B (M-20: sc-6217), anti-NF-1 (H-300: sc-5567
X), anti-Oct-1 (C-21: sc-232 X), anti-Oct-6 (H-13: sc-
11660 X) and anti-YY1 (H-414: sc-1703 X) were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Western blot analysis
Cells were cultured in 100-mm dishes for two days.
Cytoplasmic and nuclear extracts were prepared using
NE-PER Nuclear and Cytoplasmic Extraction Reagents.
Protein concentrations were determined using the BCA
Protein Assay Reagent. For FABP7 Western blot, cyto-
plasmic extracts (20 μg) were electrophoresed through
an 18% (w/v) polyacrylamide-SDS gel. The proteins
were electrophoretically transferred onto a PVDF mem-
brane. Membrane was incubated with 1 mg/mL FABP7
antibody diluted 1:5000, and antibody-antigen com-
plexes were visualized with peroxidase-conjugated anti-
goat IgG and Immobilon Western HRP Substrate. For
BRN2 Western blot, nuclear extracts (20 μg) were elec-
trophoresed through a 10% (w/v) polyacrylamide-SDS
gel. Membrane transferring proteins was incubated with
anti-Brn-2 (sc-6029 X) diluted 1:2000, and antibody-
antigen complexes were visualized with peroxidase-con-
jugated anti-goat IgG and Immobilon Western HRP
Substrate.
Promoter constructs
The pGL4-FABP7 promoter construct was generated by
cloning a 2.1-kb PCR fragment of the human FABP7
promoter region into pGL4.17. PCR reactions, using the
primers listed in Table 3, were performed to generate
promoter region deletions, each ending at position +89
bp from the transcription start site. Amplified DNA
fragments were digested with BglII and HindIII and,
using DNA Ligation Kit Ver.2.1, ligated to BglII and
HindIII-digested pGL4.17 [41].
Table 2 RT-PCR and Q-PCR primers
cDNA Sequence Annealing
temperature
(°C)
Number
of cycles
FABP7 TGACCAACAGTCAGAACTTT 54 40
GCCATCCCATTTCTGTATGTG
TBP TTCGGAGAGTTCTGGGATTGTA 58 40
TGGACTGTTCTTCACTCTTGGC
BRN2 CGGCGGATCAAACTGGGATTT 57 40
TTGCGCTGCGATCTTGTCTAT
OCT1 GCATCCAACCACCAATTTGC 57 30
GAGGTGAGGGTGATGCTTG
OCT6 GCGGCGCATCAAGCTGGG 63 38
CGGTTGCAGAACCAGACGCG
NFIA CAGCCAAGTGACGCTGACA 60 25
CCTCATTGCTCCTGGACTCAT
NFIB
(1)
CATAACCCAGGGAACTGGAG 60 25
CTCTTTCGTGCCATGTTCGAC
NFIB
(2)
CTCCCATCTGTCTCACTCAGG 58 25
CACGGGTGCTTCTTGCCAGTC
NFIC GGACAGGGATGGGCTCTG 58 35
CGTTCTTCTGAGGCCAGTGC
NFIX GTTTTGTGACTTCCGGGGTCTG 58 35
GGAAGGAGGGGAGGTGATG
b-
actin
CAAACATGATCTGGGTCATCTTCTC 60 25
GCTCGTCGTCGACAACGGCTC
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Page 10 of 12Luciferase reporter assay
Human RCC and HEK293 cell lines were grown at 37°C
in GIBCO
® RPMI Media 1640 supplemented with 10%
(v/v) fetal bovine serum in a humidified, 5% CO2 atmo-
sphere. Cells (5 × 10
4 or 7 × 10
4) were added to each
well in 24 well plates and cultured for one day. Cells
were transiently co-transfected with the pGL4-FABP7
promoter construct (0.4 μg), pGL4.74 plasmid (0.1 μg),
and 2 μL or 2.5 μL FuGENE
® HD Transfection Reagent.
One day after transfection, luciferase activity was mea-
sured with a Dual-Luciferase
® Reporter (DLR™) Assay
System using a Lumicounter 700 (Microtech Niti-On,
Japan).
Gel mobility shift analysis
Gel retardation assays were carried out using a slightly
modified version of the method described by Bisgrove et
al. [17]. Complementary oligonucleotides (Table 1) were
annealed by heating at 95°C for 2 min and then cooling
to room temperature. Probes were labeled with [g-
32P]
dATP using T4 polynucleotide kinase and then purified
using Illustra MicroSpin G-25 columns. Nuclear extracts
were prepared using NE-PER Nuclear and Cytoplasmic
Extraction Reagents. For each assay, 5 μgo fn u c l e a r
extract was used. Binding reactions were performed in
30 μl binding buffer (20 mM HEPES pH 7.9, 20 mM
KCl, 1 mM spermidine, 10 mM dithiothreitol, 10% (v/v)
glycerol, 0.1% (v/v) NP-40, and 2 μgo fp o l y ( d I - d C ) ) .
Two microliters of 5 μM unlabeled competitor oligonu-
cleotide or 1 μLo f2μg/μLa n t i b o d yw e r ea d d e da s
appropriate. Following addition of the nuclear extract
and incubation for 30 min on ice, 1 μLo f1 0 0n M
labeled probe was added and incubated for 20 min at
room temperature. DNA binding reactions were electro-
phoresed through a 6% (w/v) polyacrylamide gel in 0.5
× TBE to separate unbound probe from probe-protein
complexes.
siRNA transfection
The BRN-2 siRNA sequences used were as follows: 5’-
GTGCAGACGCCCGTCCAG-3’ (BRN2.1; [42]) and 5’-
CCGCAGCGTCTAACCACTA-3’ BRN2.2; [43]). The
scrambled control siRNA sequence was 3’-AAGTC-
CATGGTGACAGGAGAC-5’ (SC; [43]). The siRNA was
transfected into cells using X-tremeGENE siRNA Trans-
fection Reagent according to the manufacturer’s instruc-
tions. HEK293 cells were harvested 3 to 4 days after
transfection.
Additional material
Additional file 1: Data of Q-PCR and luciferase reporter assay. Figure
1A, B, 3A, B, C and 7A - unprocessed data.
Additional file 2: FABP7 Western blot covering the full range.
Western blot was performed using cytoplasmic extracts from HEK293
and RCC (TUHR14TKB, OS-RC-2, 786-O, 769-P, Caki-1, and ACHN) cell lines.
Additional file 3: Gel shift analysis with the DP probe.A )
32P-labeled
DP (Table 1 and Figure 4) was added to HEK293 or RCC (769-P, 786-O,
ACHN, Caki-1, OS-RC-2, and TUHR14TKB) nuclear extracts. In (+) cell line,
luciferase activity of -48+89 vector transfectant was increased above 30%
than that of -36+89 vector transfectant. Arrowheads indicate significant
band shifts. B) Competition analysis was performed using a variety of
oligonucleotides (Table 1). A 100-fold excess of unlabeled competitor
oligonucleotide, indicated in the figure, was added to each reaction. C)
Five micrograms of HEK293 or 786-O nuclear extracts were incubated
with 2 μg of the antibodies, as indicated in the figure, on ice for 30 min
prior to addition of the
32P-labeled oligonucleotide probes.
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Table 3 PCR primers used to prepare pGL4-FABP7
promoter constructs
Position, cloning site and
orientation
Sequence
-1122 BglII Sense CTTTCAGATCTGGTCAGCACTAGTAAG
-468 BglII Sense CACTAAGATCTCTCCTTTGTCTGCAAAG
-351 BglII Sense ATCTTAGATCTTTTCCTTGCAGTCTGAG
-192 BglII Sense GAACTAGATCTACTCCGCTAACCCAG
-149 BglII Sense CAAAGAGATCTGGAGCCTCACTCGAGC
-83 BglII Sense AGAGGAGATCTGGAGGGGTGTGTTTG
-72 BglII Sense GAGAGATCTGTTTGCAATTTAAATCACTGG
-61 BglII Sense TTTGAGATCTAAATCACTGGATTTTTGCCC
-48 BglII Sense TCACAGATCTTTTGCCCACCCTCTTTCC
-36 BglII Sense CCCAAGATCTTTCCAAATAAGAAGGCAG
+89 HindIII Antisense ACAGAAAGCTTCCACCATCCTTGCCC
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